Please assess the completion status of the following clinical trial:

Trial Title: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 18 years~* Documented evidence of NSCLC (Stage IIIB/ IV disease)~* Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC~* World Health Organization (WHO) Performance Status of 0 or 1~* Estimated life expectancy more than 12 weeks~Exclusion Criteria:~* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4~* Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)~* Active or prior documented autoimmune disease within the past 2 years~* Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIV~* Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) \>Grade 2 from previous anti-cancer therapy~* Known EGFR TK activating mutations or ALK rearrangements~* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1~* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (durvalumab) monotherapy in Sub-study A (Type: EXPERIMENTAL): MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
- Standard of Care in Sub-study A (Type: ACTIVE_COMPARATOR): Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
- MEDI4736 (durvalumab) + tremelimumab in Sub-study B (Type: EXPERIMENTAL): MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
- Standard of Care in Sub-study B (Type: ACTIVE_COMPARATOR): Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
- MEDI4736 (durvalumab) monotherapy in Sub-study B (Type: EXPERIMENTAL): MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
- tremelimumab in Sub-study B (Type: EXPERIMENTAL): tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

Based on this trial design, predict the completion outcome and termination type (if applicable).